This bill amends existing law to permit the disclosure of genetic testing or genetic analysis to clinical entities involved in a patient's care. It emphasizes that such disclosures are permissible when used for diagnosis and treatment, provided that the clinical laboratory has received a specimen referral from the patient's treating physician, genetic counselor, or another clinical laboratory. The bill also clarifies that specific informed consent from the patient is still required when genetic testing or genetic analysis is disclosed for clinical research purposes.

The bill repeals and reenacts RSA 141-H:2, IV, which outlines the conditions for genetic testing. The new language inserted into the law allows for the disclosure of genetic information to entities participating in the patient's clinical care and maintains the necessity for informed patient consent for clinical research. There are no deletions indicated in the provided text. The act was approved on August 4, 2023, and will become effective on October 3, 2023.

Statutes affected:
Introduced: 141-H:2
As Amended by the Senate: 141-H:2